Trial Profile
A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Glomerulonephritis
- Focus Therapeutic Use
- 02 Jul 2020 Primary endpoint has not been met. (Change in 24 Hour Creatinine Clearance)
- 02 Jul 2020 Results published in the Nephrology Dialysis Transplantation
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.